Shafak Aluwini

Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial

Luca Incrocci, Ruud C. Wortel, Wendimagegn Alemayehu et al. · The Lancet Oncology · 2016 · 478 citations

Medicine, Radiation Oncology, Urology +14

Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial

Shafak Aluwini, Floris J. Pos, Erik C. Schimmel et al. · The Lancet Oncology · 2016 · 313 citations · Full text

Medicine, Oncology, Radiation Oncology +16

Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial

Shafak Aluwini, Floris J. Pos, Erik C. Schimmel et al. · The Lancet Oncology · 2015 · 182 citations · Full text

Medicine, Oncology, Radiation Oncology +16

Texture analysis of 3D dose distributions for predictive modelling of toxicity rates in radiotherapy

Linda Rossi, Rik Bijman, W. Schillemans et al. · Radiotherapy and Oncology · 2018 · 125 citations

Medicine, Oncology, Radiation Oncology +17

Outcome of four-dimensional stereotactic radiotherapy for centrally located lung tumors

Joost J. Nuyttens, Noëlle C. van der Voort van Zyp, J. Praag et al. · Radiotherapy and Oncology · 2012 · 105 citations

Medicine, Oncology, Radiation Oncology +12